{"id":"https://genegraph.clinicalgenome.org/r/f1ebfc76-3a5d-40f0-8dbe-37cfecc338c6v1.0","type":"EvidenceStrengthAssertion","dc:description":"CFI was first reported in relation to autosomal dominant atypical hemolytic uremic syndrome (aHUS) in 2004 (Fremeaux-Bacchi et al., PMID: 15173250). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in phenotypic variability. Therefore, the following diseases have been split into separate entities, aHUS (OMIM: 612923) and C3 glomerulopathy (C3G) (OMIM: 610984). The split curation for autosomal dominant C3G will be conducted separately. Thirteen variants (missense, nonsense, and frameshift) that have been reported in thirteen probands in four publications (PMIDs: 15173250, 15917334, 17597211, 20016463) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is known to be loss of function, causing dysregulation of the complement mediated immune pathway. This gene-disease relationship is also supported by biochemical functions indicating the role of CFI in the complement pathway and protein interaction with CFH (PMID: 28671664). Of note, enrichment of CFI rare genetic variants has been demonstrated in aHUS in two studies using burden type testing (PMIDs: 29500241, 30377230). It should also be noted that a recent analysis of the genotyping data from UK biobank aimed to identify CFI variants that are known to result in low levels of factor I and identified no cases of aHUS with any of the 1,671 type 1 variants, demonstrating very low penetrance for CFI. In summary, there is definitive evidence supporting the relationship between CFI and autosomal dominant aHUS. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Complement Mediated Kidney Diseases GCEP on the meeting date June 1, 2023 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/f1ebfc76-3a5d-40f0-8dbe-37cfecc338c6","GCISnapshot":"https://genegraph.clinicalgenome.org/r/3a5fcd7c-0da5-4ba3-b0c6-2d40f985c418","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/3a5fcd7c-0da5-4ba3-b0c6-2d40f985c418_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10069","date":"2023-06-01T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/3a5fcd7c-0da5-4ba3-b0c6-2d40f985c418_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10069","date":"2023-06-30T18:18:14.165Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a5fcd7c-0da5-4ba3-b0c6-2d40f985c418_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a5fcd7c-0da5-4ba3-b0c6-2d40f985c418_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33c9bb4d-a60d-408c-be1f-c6581a3167c2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/125b9ae4-71e0-4487-8ec9-28cfc50c0fd3","type":"Finding","dc:description":"The inability to drive opsonization directly contributes to aHUS.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28671664","rdfs:label":"FI-mediated cleavage","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c75f33ef-e3ce-4d10-bf97-1a485df3e7bd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11e346d9-79d3-45a6-b1a8-2df857baa184","type":"Finding","dc:description":"FH assists in binding FI to the C3b–FH complex and the complex activates FI to cleave C3b at its first cleavage site. FI binds C3b–FH primarily at the CTC domain of C3b and domains CCP2–3 of FH. Interactions between C3b–FH and FI contribute, either directly or indirectly, to stabilization of the catalytic SP domain of FI and hence induce proteolytic activity to the enzyme.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28671664","rdfs:label":"Interaction with FH","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3a5fcd7c-0da5-4ba3-b0c6-2d40f985c418_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ffa4f84-1c63-43cf-947b-dee964ff5fc2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ffa4f84-1c63-43cf-947b-dee964ff5fc2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The quantity of FI in the supernatants was determined by ELISA using sheep anti-FI, demonstrating a quantitative deficiency of the protein.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3ffa4f84-1c63-43cf-947b-dee964ff5fc2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20016463","allele":{"id":"https://genegraph.clinicalgenome.org/r/d6da312c-3881-4f62-89f4-6aeb11175ac9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.128G>T (p.Cys43Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357865652"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c6767705-0bcf-455a-a985-fa2987fc3bca","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6767705-0bcf-455a-a985-fa2987fc3bca_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No generation of α1 cleavage fragment, kinetic analysis of C3b cleavage showed little if any activity, no detectable or minimal activity for C4b cleavage","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c6767705-0bcf-455a-a985-fa2987fc3bca_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17597211","allele":{"id":"https://genegraph.clinicalgenome.org/r/0a6e63b0-68cf-40a7-b62e-e4839c35115c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.1019T>C (p.Ile340Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3042048"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/03353efd-4505-4029-b116-76b5094c2d36","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/03353efd-4505-4029-b116-76b5094c2d36_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The quantity of FI in the supernatants was determined by ELISA using sheep anti-FI, demonstrating a quantitative deficiency of the protein.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/03353efd-4505-4029-b116-76b5094c2d36_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20016463","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ffca247-259f-4c3a-8363-7c7989ddeb47","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.786del (p.Gly263AlafsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3042164"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a1ff7502-9564-4b25-92f4-34522ca51783","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a1ff7502-9564-4b25-92f4-34522ca51783_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Only a faint α1 band could be seen, consistent with loss of cofactor activity. The variant demonstrated C3b and C4b cleavage substantially slower than the WT. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a1ff7502-9564-4b25-92f4-34522ca51783_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17597211","allele":{"id":"https://genegraph.clinicalgenome.org/r/0aaca0a5-0d2e-4445-8f97-e57325056b0d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.1555G>A (p.Asp519Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA256223"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/df88fdf4-c8c3-46bc-820b-e426aa3ca50e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df88fdf4-c8c3-46bc-820b-e426aa3ca50e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The quantity of FI in the supernatants was determined by ELISA using sheep anti-FI, demonstrating a quantitative deficiency of the protein.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/df88fdf4-c8c3-46bc-820b-e426aa3ca50e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20016463","allele":{"id":"https://genegraph.clinicalgenome.org/r/9aa14e19-fb6e-46fc-b300-9baa52a09f6f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.1291G>A (p.Ala431Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3041950"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0e9cc7c8-641d-4458-aa36-1bcf5ffed6be","type":"EvidenceLine","dc:description":"This nonsense variant is not predicted to cause NMD.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e9cc7c8-641d-4458-aa36-1bcf5ffed6be_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of Supernatant was 8% of WT, expression of Lysate was 27.5% of WT (de Jong et al. 2020, PMID: 32510551)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0e9cc7c8-641d-4458-aa36-1bcf5ffed6be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15173250","allele":{"id":"https://genegraph.clinicalgenome.org/r/8acbe480-3a20-40e7-8f79-9929deaaaac2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.1637G>A (p.Trp546Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA256217"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4925a747-8d07-456e-9cdd-ccc25d72a7e4","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4925a747-8d07-456e-9cdd-ccc25d72a7e4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15917334","allele":{"id":"https://genegraph.clinicalgenome.org/r/f09dce85-032b-4c6b-bd68-860c19de03f8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.893del (p.Ser298LeufsTer2)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA785235457"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e600c1e8-189c-42da-ac60-11b9a02cd5b6","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e600c1e8-189c-42da-ac60-11b9a02cd5b6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of supernatant was 9.5% of WT, expression of lysates was 28% of WT (de Jong et al. 2020, PMID: 32510551)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e600c1e8-189c-42da-ac60-11b9a02cd5b6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15917334","allele":{"id":"https://genegraph.clinicalgenome.org/r/416cac9e-35e0-4f34-8bc5-786e90628f48","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.434G>A (p.Trp145Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357863868"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/28fca5ed-ae23-4862-9afa-e331d005ccfa","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/28fca5ed-ae23-4862-9afa-e331d005ccfa_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of Supernatant was 7% WT, expression of Lysate was 17.5% WT (de Jong et al. 2020, PMID: 32510551)\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/28fca5ed-ae23-4862-9afa-e331d005ccfa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15173250","allele":{"id":"https://genegraph.clinicalgenome.org/r/e75e4b1f-98cd-45cc-a036-80366274073f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.1420C>T (p.Arg474Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA256211"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/47543bbd-3295-4a8a-a92e-3300967dfb08","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47543bbd-3295-4a8a-a92e-3300967dfb08_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The quantity of FI in the supernatants was determined by ELISA using sheep anti-FI, demonstrating a quantitative deficiency of the protein.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/47543bbd-3295-4a8a-a92e-3300967dfb08_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20016463","allele":{"id":"https://genegraph.clinicalgenome.org/r/a2297faa-da2c-46e3-8523-bae15b7458f9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.452A>G (p.Asn151Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3042272"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/110550cf-3fa1-4c11-bce5-2845dde9ec7c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/110550cf-3fa1-4c11-bce5-2845dde9ec7c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The quantity of FI in the supernatants was determined by ELISA using sheep anti-FI, demonstrating a quantitative deficiency of the protein.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/110550cf-3fa1-4c11-bce5-2845dde9ec7c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20016463","allele":{"id":"https://genegraph.clinicalgenome.org/r/59ad721a-f571-4a76-a2fe-e6c7c85b50c0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.148C>G (p.Pro50Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3042342"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0015076f-be6c-45ba-8d63-47e60c919113","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0015076f-be6c-45ba-8d63-47e60c919113_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The quantity of FI in the supernatants was determined by ELISA using sheep anti-FI, demonstrating a quantitative deficiency of the protein.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0015076f-be6c-45ba-8d63-47e60c919113_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20016463","allele":{"id":"https://genegraph.clinicalgenome.org/r/b569d127-67cd-47cb-994f-52667693be6d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.1367G>T (p.Trp456Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357856709"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e34822e4-d730-42a2-83f5-47abacbf4373","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e34822e4-d730-42a2-83f5-47abacbf4373_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No generation of α1 cleavage fragment. Kinetic analysis of C3b cleavage showed little if any activity. No detectable or minimal activity for C4b cleavage (Kavanagh et al. 2008, PMID: 17597211).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e34822e4-d730-42a2-83f5-47abacbf4373_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15173250","allele":{"id":"https://genegraph.clinicalgenome.org/r/972f40be-2748-45fd-84a4-d474d08574b6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000204.5(CFI):c.1571A>T (p.Asp524Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA256214"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":6577,"specifiedBy":"GeneValidityCriteria9","strengthScore":13,"subject":{"id":"https://genegraph.clinicalgenome.org/r/VffUUx1xsic","type":"GeneValidityProposition","disease":"obo:MONDO_0016244","gene":"hgnc:5394","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_3a5fcd7c-0da5-4ba3-b0c6-2d40f985c418-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}